Log in
Pioneering research at the University of Chichester lead by Professor Harris provided in 2006 first evidence on the effectiveness of beta-alanine supplementation in augmenting carnosine content in human skeletal muscle. Subsequent studies demonstrated the performance-enhancing effect of beta-alanine supplementation, particularly in high-intensity exercise. The research was exploited by a US company through a number of worldwide patents based on Harris' work achieving sales and license revenues of $4.8M in 2013 fiscal year alone. Beta-alanine supplementation has emerged as a legal means to enhance performance taken up at amateur and elite level sport worldwide; it is having global impact on the sports nutrition industry.
This case study focuses on the development and usage of self-help material designed to aid people in feeling and performing better. It has achieved impact through raising awareness via mass media and professional outlets. Research informed self-help materials are available for open access via media links, academic organisations, service organisations (NHS), commercial organisations (London Marathon), national governing bodies (Research Councils), and professional bodies (British Association of Sport and Exercise Sciences). An on-line project, run in conjunction with BBC Lab UK, developed and tested self-help interventions with 75,000 users each receiving personalised feedback from former Olympian Michael Johnson.
The Human Performance Research Group at Aberystwyth University developed a novel high- intensity "warm-up" regime, known as "priming exercise". Performing this type of exercise can provide an ergogenic effect during subsequent exercise or competition. This research has impacted upon professional practice of sports scientists and coaches tasked with preparing elite athletes for competition. Specifically, previously warm-up exercise was performed prior to exercise, whereas now many practitioners apply priming exercise regimes. In addition, this practice has a direct impact upon the performance of both elite and amateur athletes.
A 20 year collaborative programme of research and physiological monitoring between the Royal Yachting Association (RYA) and the University of Chichester (UC) has significantly impacted upon training and competitive strategies adopted by the RYA to maintain world class sailing performance within the REF period. Research conducted in the period 1993-2004 provided the first empirical evidence base to underpin training for dingy and boardsailing. This provided the foundation to develop training guidelines for youth and elite sailors, contributing to successful sailing performances in the past five Olympic games. The guidelines are now freely accessible online for recreational sailors.
King's College London (KCL), operating a state-of-the-art Drug Control Centre (DCC) in collaboration with GlaxoSmithKline (GSK), delivered the anti-doping analysis at the London 2012 Olympic and Paralympic Games. This operation, undertaken in their World Anti-Doping Agency's (WADA) accredited laboratories, was characterised by unprecedented scale, speed and accuracy. It succeeded in protecting the health of athletes and the integrity of the Games. KCL was chosen to undertake the 24/7 anti-doping operation based on its cutting-edge bio-analytical research in drug control. Although a number of athletes were disqualified in the pre-Games testing, the deterrent effect of the KCL work was evidenced by the few doping cases during the Games itself. Using the new biomarker test developed by the DCC at KCL in collaboration with colleagues at the University of Southampton, the team identified for the first time the administration of recombinant human growth hormone (hGH) in two athletes. The findings of the KCL-led operation are already being used to develop similar testing facilities for the 2016 Olympic Games in Rio de Janeiro and have opened up the science of drug-testing to schools through the "Scientists in Sport" initiative.
Mathematically-based image processing techniques developed at the University of Cambridge have helped bring about a revolution in the ability to extract quantitative measurements from laboratory experiments in fluids. Techniques and software tools developed from this research and incorporated into commercial software are now used in engineering, physics and mathematics research laboratories around the world on projects ranging from fundamental research to ones with strong industrial connections.
Research by Alison McConnell and colleagues has underpinned the creation of a new category of exercise training and rehabilitation; "breathing training" improves exercise tolerance and reduces perceived exertion. McConnell invented the market-leading POWERbreathe® breathing trainer, and since joining Brunel (2000), has led further new product developments via Knowledge Transfer Partnerships (KTP) and consultancy. Research by McConnell and her team underpins marketing by POWERbreathe® and several "copycat" products serving UK and overseas markets. Impacts include: 1. physiological benefits to individual users globally, from elite athletes to patients; and 2. commercial benefits to POWERbreathe International Ltd., its supply chain, and to new international businesses serving the breathing training market created by POWERbreathe®.
Essex research identified a novel bioprocessing matrix which has since been developed into commercial products and recently launched into external markets by Porvair Filtration Group Ltd. The discovery involved the chemical modification of sintered thermoplastic materials in order to attach biological molecules, so conferring highly specific functionalised properties to an otherwise inert base material. This enabled a new approach for protein immobilisation, having technical and practical advantages over existing processes. As a direct result, Porvair has adopted a new technology and invested £900k in R&D over eight years. Essex research has supported a change in business strategy, enabling entry into new markets, which has in turn both safeguarded and created jobs at Porvair.
This case study illustrates the development of novel research materials designed to improve quality of life and performance in different populations. Impact has been achieved through the use of research findings in professional practice, formulation of health-related policies and in the development of new indicators of health and well-being. RCSEP research has been used by international and national health-service organisations (e.g., European League Against Rheumatism, Evidence NHS), industrial establishments (e.g., ArtEZ Conservatoire, Netherlands; Royal Ballet), national governing bodies (British Heart Foundation), and professional bodies (e.g., Dance UK, International Association of Dance Medicine & Science).
Knowledge of the three-dimensional structures of macromolecules is a prerequisite for understanding their function at the atomic level, an essential component of modern drug development. Most structures are determined by X-ray crystallography: the majority using molecular replacement (MR, which exploits known structures of related proteins), and about half of the remainder using single-wavelength anomalous diffraction (SAD). The Phaser crystallographic software, developed by Read and colleagues, implements powerful new likelihood-based methods for MR and SAD phasing and has made a large impact, accelerating over the period 2008-2013. At the pharma giant, AstraZeneca, Phaser is considered the "tool of choice" for solving structures by MR.